BioSpace News Archive

Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham’s High Flux Accelerator-Driven Neutron Facility.

Theratechnologies Inc. today announced that the United States Food and Drug Administration (FDA) has approved the company’s Labelling Prior Approval Supplement to include a 2000-mg intravenous (IV) push loading dose for Trogarzo® (ibalizumab-uiyk).

Rezolute, Inc. today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema (“DME”).

Acasti Pharma Inc. today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.

BioAtla, Inc. today is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent.

BioVaxys Technology Corp. announced today that it is in non-binding discussions to acquire an immunotherapeutics intellectual property portfolio of discovery, preclinical and clinical development stage assets in oncology and other immunological fields formerly owned by an unnamed biotechnology company and now held by the secured creditor.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the launch of Biovelocita, an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.

Novozymes and Chr. Hansen announced their future name ‘Novonesis’. The name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

BioLabs and Promega announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies.

Shattuck Labs, Inc. today announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.